Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: Translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design

Journal of Thrombosis and Thrombolysis

Volumn 32, Issue 1, 2011, Pages 21-31

  Povsic, T J ^a   Cohen, M G ^b   Chan, M Y ^a   Zelenkofske, S L ^c   Wargin, W A ^d   Harrington, R A ^a   Alexander, J H ^a   Rusconi, C P ^e   Becker, R C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Regado Biosciences   (United States)

^d PK PM Associates LLC   (United States)

^e Regado Biosciences   (United States)

Author keywords

Anivamersen; Dose s.election.; Factor IXa inhibition; Pegnivacogin

Indexed keywords

ANIVAMERSEN; BLOOD CLOTTING FACTOR 9A; BLOOD CLOTTING INHIBITOR; PEGNIVACOGIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DEPLETION; SINGLE DRUG DOSE;

ANTICOAGULANTS; APTAMERS, NUCLEOTIDE; ARGENTINA; FACTOR IX; FEMALE; HUMANS; MALE; MODELS, THEORETICAL; OLIGONUCLEOTIDES; PARTIAL THROMBOPLASTIN TIME; TIME FACTORS; UNITED STATES;

EID: 80052480929     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-011-0588-3     Document Type: Article

References (8)

1. Dyke CK, Steinhubl SR, Kleiman NS, Cannon RO, Aberle LG, Lin M, Myles SK, Melloni C, Harrington RA, Alexander JH, Becker RC, Rusconi CP (2006) Firs-in-human experience of an antidotecontrolledanticoagulant using RNA aptamertechnology: a phase1a pharmacodynamic evaluation of a drug-antidote pair for thecontrolled regulation of factor IXa activity. Circulation 114(23)2490-2497 (Pubitemid 44901522)
2. Howard EL, Becker KCD, Rusconi CP, Becker RC (2007) Factor IXa inhibitors as novel anticoagulants. Arterioscler Thromb VascBiol 27(4):722-727 (Pubitemid 46606698)
3. Rusconi CP, Scardino E, Layzer J, Pitoc GA, Ortel TL, Monroe D, Sullenger BA (2002) RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419(6902):90-94 (Pubitemid 34987876)
4. Chan MY, Cohen MG, Dyke CK, Myles SK, Aberle LG, Lin M, Walder J, Steinhubl SR, Gilchrist IC, Kleiman NS, Vorchheimer DA, Chronos N, Melloni C, Aleander JH, Harrington RA,Tonkens RM, Becker RC, Rusconi CP (2008) Phase 1b randomizedstudy of antidote-controlled modulation offactor IXa activityin patients with stable coronary artery disease. Circulation117(22):2865-2874 (Pubitemid 351787073)
5. Chan MY, Rusconi CP, Alexander JH, Tonkens RM, Harrington RA, Becker RC (2008) A randomized, repeat-dose, pharmacodynamicand safety study of an antidote-controlled factor IXainhibitor. J Thromb Haemost 6(5):789-796 (Pubitemid 351524539)
6. Cohen MG, Purdy DA, Rossi JS, Grinfeld LR, Myles SK, Aberle LG, Greenbaum AB, Fry E, Chan MY, Tonkens RM, Zelenkofske S, Alexander JH, Harrington R Rusconi CP, Becker RC (2010)First clinical application of an actively revesible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous intervention. Circulation 122(6):614-622
7. Gopinath SCB, Shikamoto Y, Mizuno H, Kumar PKR (2006) Apotent anti-coagulant RNA aptamer inhibits blood coagulation by specficially blocking the extrinsic clotting pathway. Thromb Haemost 95(5):767-771
8. Povsic TJ, Cohen MG, Mehran R, Buller CE, Bode C, Cornel JH, Kasprzak JD, Montalescot G, Joseph D, Wargin WA, Rusconi CP, Zelenkofske SL, Becker RC, Alexander JH (2011) A randomized, partially blinded, multicenter, active-controlled, dose-rangingstudy assessing the safety, efficacy, and pharmacodynamics ofthe REG1 anticoagulation system in patients with acute coronarysynromes: design and rationale of the RADAR phase IIb trial. Am Heart J 161(2):261-268